109 Antibody Drug Conjugates Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.
| wdt_ID | No. | Developer Name | ADC Name / Code | Target | Phase | Indication | NCT Number |
|---|---|---|---|---|---|---|---|
| 1 | 1 | Angiochem, Inc. | ANG1005 | LRP-1 | III | Leptomeningeal Metastases | NCT03613181 |
| 2 | 2 | Astellas Pharma, Inc. | Enfortumab vedotin | Nectin-4 | III | Muscle Invasive Bladder Cancer | NCT04700124 |
| 3 | 3 | Byondis B.V. | SYD985 | Her2 | III | Metastatic Breast Cancer | NCT03262935 |
| 4 | 4 | Daiichi Sankyo Company, Limited | Datopotamab deruxtecan / DS-1062 | TROP2 | III | Non-small Cell Lung Cancer | NCT04656652 |
| 5 | 5 | ImmunoGen, Inc. | Mirvetuximab Soravtansine/ IMGN853 | FOLR1 | III | Epithelial Ovarian Cancer | NCT04296890 |
| 6 | 6 | Rakuten Medical, Inc. | RM-1929/ ASP-1929 | EGFR | III | Head and Neck Cancer | NCT02422979 |
| 7 | 7 | RemeGen, Co., Ltd. | Disitamab vedotin/ RC48 | HER2 | III | Breast Cancer | NCT03507166 |
| 8 | 8 | Sanofi SA | Tusamitamab ravtansine / SAR 408701 | CEACAM5 | III | Metastatic Non Small Cell Lung Cancer | NCT04154956 |
| 9 | 9 | Abbive Inc | Telisotuzumab vedotin / ABBV-399 | cMet | II | Non Small Cell Lung Cancer | NCT03539536 |
| 10 | 10 | ADC Therapeutics | Loncastuximab Tesirine / ADCT-402 | CD19 | II | Diffuse Large B-cell Lymphoma | NCT03589469 |
| 11 | 11 | Bayer Healthcare AG | Anetumab ravtansine | Mesothelin | II | Pancreatic Cancer | NCT03023722 |
| 12 | 12 | Daiichi Sankyo Company, Limited | Trastuzumab deruxtecan / DS-8201 | Her2 | II | Colorectal Neoplasm | NCT03384940 |
| 13 | 13 | Daiichi Sankyo Company, Limited | Patritumab Deruxtecan / U3 1402 | Her3 | II | Metastatic Colorectal Cancer | NCT04479436 |
| 14 | 14 | Debiopharm Group | Naratuximab emtansine / Debio 1562 | CD37 | II | Diffuse Large B-Cell Lymphoma | NCT02564744 |
| 15 | 15 | Genmab A/S | Tisotumab Vedotin / HuMax-TF-ADC | Tissue Factor (TF) | II | Ovarian Cancer | NCT03657043 |
| 16 | 16 | Helix BioPharma Corp. | L-DOS47 | CEACAM6 | II | Lung Adenocarcinoma | NCT03891173 |
| 17 | 17 | Seagen Inc. | Tisotumab vedotin | TF | II | Ovarian Cancer | NCT03657043 |
| 18 | 18 | Seagen Inc. | Ladiratuzumab / SGN-LIV1A | - | II | Small Cell Lung Cancer | NCT04032704 |
| 19 | 19 | Zymeworks, Inc. | ZW49 | Her2 | II | HER2+ Cancers | NCT03821233 |
| 20 | 20 | Bicycle Therapeutics Ltd. | BT1718 | MMP-14 | I/II | Advanced Solid Tumours | NCT03486730 |
| 21 | 21 | Bicycle Therapeutics Ltd. | BT5528 | EphA2 | I/II | Non Small Cell Lung Cancer | NCT04180371 |
| 22 | 22 | BioAtla LLC | BA3021 / CAB-ROR2-ADC | ROR2 | I/II | Solid Tumor | NCT03425279 |
| 23 | 23 | BioAtla LLC | BA3011 / CAB-AXL-ADC | AXL | I/II | Solid Tumor | NCT03504488 |
| 24 | 24 | Bolt Biotherapeutics, Inc. | BDC-1001 | Her2 | I/II | Advance Solid Tumors | NCT04278144 |
| 25 | 25 | Bristol-Myers Squibb | BMS-986148 | Mesothelin | I/II | Advanced Solid Tumors | NCT02341625 |
| Developer Name | ADC Name / Code | Target | Phase | Indication | NCT Number |